John Renger - Aug 10, 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
Chief Scientific Officer
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Aug 10, 2022
Transactions value $
-$1,863,075
Form type
4
Date filed
8/12/2022, 04:15 PM
Previous filing
Aug 9, 2022
Next filing
Oct 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $104K +29.6K +1095.56% $3.50* 32.3K Aug 10, 2022 Direct F1
transaction CERE Common Stock Options Exercise $261K +25.4K +78.5% $10.28 57.7K Aug 10, 2022 Direct F1
transaction CERE Common Stock Sale -$1.45M -36.1K -62.63% $40.19 21.6K Aug 10, 2022 Direct F1, F2
transaction CERE Common Stock Sale -$775K -18.9K -87.46% $41.10 2.7K Aug 10, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -29.6K -26.99% $0.00 80.1K Aug 10, 2022 Common Stock 29.6K $3.50 Direct F1, F4
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -25.4K -15.83% $0.00 135K Aug 10, 2022 Common Stock 25.4K $10.28 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.57 - $40.565. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.57 - $41.415. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.